Neurological Disorder Compounds Modifying SCD and Protein Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as Parkinson's Disease and Alzheimer's Disease provide limited relief due to an incomplete understanding of molecular perturbations and a lack of robust model systems, necessitating the development of therapies that can alter the course of these disorders.
Innovation Solution
Development of compounds with specific structures, such as those represented by Formula Ic, and their pharmaceutical compositions for use in treating neurological disorders, inhibiting protein-related toxicity, and addressing stearoyl-CoA desaturase (SCD)-associated disorders, including SCD5-associated disorders, by administering effective amounts of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for neurodegenerative diseases, then some symptom relief is achieved, but the course of the disease cannot be altered and quality of life remains poor
Solution Approach 1:
The patent applies parameter changes by modifying molecular parameters of therapeutic agents through specific chemical structure modifications (Formula I compounds with varying R1, R2, L1 groups) to achieve both symptom relief and disease modification, transforming the traditional binary outcome of therapy effectiveness
2Loss of information
If existing model systems are used for disease research, then some insights are obtained, but robust model systems are lacking and therapeutic development is limited
Solution Approach 1:
The patent employs intermediary compounds (Formula I molecules) that serve as mediators between current therapeutic limitations and desired disease modification, enabling translation of molecular insights into effective therapies by bridging the gap between model system findings and clinical application
3Productivity
If therapies are developed without robust model systems, then development speed is maintained, but therapeutic effectiveness and reliability are compromised
Solution Approach 1:
The patent implements preliminary action by pre-establishing robust preclinical model systems and conducting extensive in vitro and in vivo testing before clinical translation, ensuring therapeutic reliability is built into the development process rather than added as an afterthought, thus maintaining both speed and effectiveness
Data Source
AI summary
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.